Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to attention deficit hyperactivity disorder (ADHD), attention deficit disorder (ADD), and autism spectrum disorder (ASD) through overlapping neurodevelopmental, immunological, and symptomatic pathways.
Children and adolescents with neurodivergent traits, including ADHD and autism, are at increased risk of experiencing chronic disabling fatigue, which shares clinical features with ME/CFS. Longitudinal cohort data indicate that children scoring above screening thresholds for autism or ADHD at ages 7 and 9 have approximately twice the likelihood of developing chronic disabling fatigue by age 18, even after controlling for depression. Elevated inflammatory markers, particularly interleukin-6 (IL-6), mediate this association, suggesting that heightened inflammation links neurodivergence with fatigue syndromes like ME/CFS Quadt et al. 2024 NICE CKS.
ME/CFS is a complex, chronic condition characterized by unrelenting fatigue worsened by exertion, cognitive difficulties, and fluctuating symptoms with substantial impact on quality of life and functioning. It involves multi-system pathophysiology including autonomic dysfunction, sensory processing abnormalities, and neurocognitive impairments (NICE CKS; NICE NG206) NICE CKS,NICE NG206.
The cognitive dysfunction typical in ME/CFS encompasses impairments in attention, processing speed, and executive function, often described as "brain fog." Mechanistic research reveals this arises not from overt neurodegeneration, but from glial activation, neurovascular unit dysfunction, and subtle neuronal network imbalances. Persistent systemic and neuroinflammation implicate activated microglia and astrocytes, altered cerebral blood flow, and dysregulation of neurotransmitter systems as contributors to these deficits Xu et al. 2026 NICE CKS.
Neurodevelopmental disorders including ASD and ADHD similarly demonstrate dysregulated neuroimmune pathways involving microglial dysfunction, altered synaptic pruning, and immune system aberrations. ASD pathophysiology involves complex neuroimmunological interactions integrating environmental exposures, genetic susceptibility, and gut-brain axis dysbiosis. Immune cell abnormalities (such as in microglia, astrocytes, natural killer cells, and mast cells), neuroinflammation, and disrupted blood–brain and gut-blood barriers have all been implicated Varia et al. 2025 Varia et al. 2025.
Shared clinical features such as attentional difficulties, cognitive slowing, sensory hypersensitivity, fatigue, and increased pain sensitivity appear across ME/CFS, ADHD, and ASD, reflecting partially overlapping neurobiological substrates. Furthermore, connective tissue disorders and altered autonomic function are comorbid in ADHD and ME/CFS, linking physiological dysregulation across these conditions Baeza-Velasco et al. 2018 Quadt et al. 2024 NICE CKS,Quadt et al. 2024.
Therapeutically, while ME/CFS and ASD remain primarily diagnosed clinically due to a lack of definitive biomarkers, recognition of immune-mediated mechanisms has prompted multidisciplinary strategies incorporating neurological, immunological, and psychosocial management (NICE NG206) NICE NG206. Increased awareness of the immune and inflammatory components common to ME/CFS, ADHD, ADD, and ASD highlight the importance of integrated screening and personalized support interventions targeting neurodevelopmental, inflammatory, and cognitive symptoms across these conditions Quadt et al. 2024 Varia et al. 2025 Quadt et al. 2024,Varia et al. 2025.
Key References
- NICE CKS: Functional neurological disorder
- NICE CKS: Attention deficit hyperactivity disorder
- NICE CKS: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
- NICE NG206: Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management
- SmPC: Meflynate XL 60 mg modified-release hard capsules
- SmPC: Meflynate XL 10 mg modified-release hard capsules
- SmPC: Meflynate XL 20 mg modified-release hard capsules
- SmPC: Meflynate XL 30 mg modified-release hard capsules
- (Bellanti et al., 2005): Are attention deficit hyperactivity disorder and chronic fatigue syndrome allergy related? what is fibromyalgia?
- (Baeza-Velasco et al., 2018): Attention-deficit/hyperactivity disorder, joint hypermobility-related disorders and pain: expanding body-mind connections to the developmental age.
- (Quadt et al., 2024): Childhood neurodivergent traits, inflammation and chronic disabling fatigue in adolescence: a longitudinal case-control study.
- (Xu et al., 2026): Neurovascular and synaptic milieu of brain-resident cells in cognitive dysfunction of myalgic encephalomyelitis/chronic fatigue syndrome.
- (Varia et al., 2025): The Neuroimmunology of Autism.